Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

[cafead]

via The Food and Drug Administration began a priority review of Bluebird bio’s gene therapy for sickle cell disease and will issue a decision by Dec. 20, the company said Wednesday.

article source